Early Conversion to Tacrolimus Vs Cyclosporine Continuation in Normally Functioning Kidney Allograft: A Single-Center Study

Laya Azizzadeh; Seyed Amirhossein Fazeli; Farshad Hashemian; Sanaz Dehghani; Seyedeh Samaneh Ahmadi; Gholamreza Pourmand

doi:10.22037/ijpr.2020.113220.14174

IJ Pharmaceutical Research

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/ijpr.2020.113220.14174

Early Conversion to Tacrolimus Vs Cyclosporine Continuation in Normally Functioning Kidney Allograft: A Single-Center Study

Author(s):

Laya Azizzadeh¹,

Seyed Amirhossein Fazeli²,

Farshad Hashemian¹,

Sanaz Dehghani³,

Seyedeh Samaneh Ahmadi⁴,

Gholamreza Pourmand^3,*

1Department of Clinical Pharmacy, Faculty of pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran

3Urology Research Center, Sina Hospital, Tehran University of Medical sciences, Tehran, Iran

4Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran

IJ Pharmaceutical Research:Vol. 19, issue 3; 556-571

Published online:Jul 31, 2020

Article type:Research Article

Received:Feb 01, 2020

Accepted:Jul 01, 2020

How to Cite:Laya AzizzadehSeyed Amirhossein FazeliFarshad HashemianSanaz DehghaniSeyedeh Samaneh AhmadiGholamreza Pourmandet al.Early Conversion to Tacrolimus Vs Cyclosporine Continuation in Normally Functioning Kidney Allograft: A Single-Center Study.Iran J Pharm Res.19(3):e127850.https://doi.org/10.22037/ijpr.2020.113220.14174.

Abstract

This study evaluated the effectiveness of early pre-emptive conversion from cyclosporine to tacrolimus in kidney transplant patients with normal graft function and in the absence of adverse effects of the initial cyclosporine. A historical cohort study of 166 patients who received deceased-donor kidney transplant between 2011 to 2017 was conducted. All the patients had been treated with cyclosporine (Sandimmune®) during their immediate post-transplantation period. At the time of hospital discharge, the patients were divided into 2 groups: patients with continued cyclosporine (Sandimmune®) treatment (n = 125) and the patients whose treatments converted from cyclosporine to tacrolimus (Prograf®) at discharge (n = 41). The 1-year graft function (p = 0.074), acute rejection (p = 0.566), and graft loss (p = 0.566) were not significantly different between two groups. The patients on tacrolimus had lower levels of cholesterol (p = 0.002) and diastolic blood pressure (p = 0.015). The long-term follow-up showed no significant difference in graft loss (p = 0.566). The patients received tacrolimus had higher all-cause mortality within the first year posttransplantation (p = 0.002) as well as long-term follow-up (p = 0.001). The continuation of initial cyclosporine might be a good option when the graft function is acceptable and the adverse effects are absent.

Keywords

Graft

Transplantation

Calcineurin inhibitors

Kidney

Immunosuppressive

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Laya Azizzadeh:[PubMed][Scholar]
Seyed Amirhossein Fazeli:[PubMed][Scholar]
Farshad Hashemian:[PubMed][Scholar]
Sanaz Dehghani:[PubMed][Scholar]
Seyedeh Samaneh Ahmadi:[PubMed][Scholar]
Gholamreza Pourmand:[PubMed][Scholar]